Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-03-22
2005-03-22
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S469000
Reexamination Certificate
active
06869939
ABSTRACT:
The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared. Solutions can be made either dilutable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.
REFERENCES:
patent: 5134127 (1992-07-01), Stella et al.
patent: 5234949 (1993-08-01), Ehrenpreis et al.
patent: 5376645 (1994-12-01), Stella et al.
patent: 5874418 (1999-02-01), Stella et al.
patent: 6046177 (2000-04-01), Stella et al.
patent: 6143778 (2000-11-01), Gautier et al.
patent: 6204256 (2001-03-01), Shalaby et al.
patent: 6218375 (2001-04-01), Raghavan et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 20020012680 (2002-01-01), Patel et al.
patent: PCTAU90/00418 (1991-04-01), None
patent: PCTAU91/00071 (1991-09-01), None
Okimoto, K. et al “The interaction of charged and uncharged drugs . . . ” Pharm. Res. (1996) vol. 13, no 2, pp. 256-264.*
Leor, R. et al “The influence of pH on the intravenous delivery . . . ” Eur. J. Clin. Pharmacol. (1990) vol. 39, pp. 521-523.*
Ward, Gary et al., Studies in Phlebitis VI: Dilution—Induced precipitation of Amiodarone HCI, Journal of Parenteral Science and Technology, vol. 47, No. 4, Jul.-Aug. 1993, 161-165.
Ravin, L.J. et al., Micelle Formation and Its Relationship to Solubility Behavior fo 2-Buty-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl Ketone Hydrochloride, Journal of Pharmaceutical Sciences, vol. 64, No. 11, Nov. 1975, 1830-1833.
Ravin, L.J., Effect of Polysorbate 80 on the Solubility and In Vivo Availability of 2-Butyl-3-benzofuranyl 4-[2-(Diethlylamino)ethoxy]-3,5-diiodophenyl Ketone Hydrochloride.
Gayed Atef A.
Johnson Karen T.
Mosher Gerold L.
Barts Samuel
CyDex, Inc.
Innovar L.L.C.
Maier Leigh C.
Matos Rick
LandOfFree
Formulations containing amiodarone and sulfoalkyl ether... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulations containing amiodarone and sulfoalkyl ether..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations containing amiodarone and sulfoalkyl ether... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406013